secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001193125-24-197065
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inovio Q2 net loss $32.2M; INO-3107 BLA submission delayed to mid-2025 due to device manufacturing issue
--------------------------------------------------------------------------------

- Net loss of $32.2M ($1.19/share) vs $35.5M ($1.61/share) in Q2 2023; revenue not disclosed.
- Cash, equivalents and short-term investments $110.4M; cash runway estimated into Q3 2025.
- BLA submission for lead candidate INO-3107 (RRP) delayed to mid-2025 due to manufacturing issue with disposable device component.
- Appointed Steve Egge as Chief Commercial Officer; submitted Phase 3 trial design for INO-3112 to European regulators.
- Raised $33.2M net in April 2024 stock/warrant offering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000119312524197065/0001193125-24-197065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000119312524197065/d681488d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-197065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer